Legacy Appoints Vice President of Sales and Marketing, Europe, Middle East, Asia and Africa
Posted on: Friday, 28 March 2008, 00:00 CDT
Legacy Pharmaceuticals International GmbH announced today that Paul Vaughan-Griffiths has been appointed to the newly created position of Vice President of Sales and Marketing, with the responsibility of overseeing the Company sales and marketing in Europe, Middle East, Asia and Africa.
"Legacy is excited to have Paul lead our EMEAA commercial efforts. He will formulate and execute our international strategy and direct the Sales and Marketing efforts. I look forward to working with him and utilizing his ability to help build our business globally. We will continue to build on our momentum in the contract manufacturing business. This appointment underscores the depth of our commitment to global growth and continued profitability. The Company will benefit from his expertise and leadership," said Mr. Michael R. Danzi, Chairman and Chief Executive Officer of Legacy.
Paul Vaughan-Griffiths has over 30 years' experience in the Pharmaceutical Industry. Prior to joining Legacy he was Head of Commercial European Operations in Prostrakan Ltd where he was involved in building the European business and for 10 years with Valeant Pharmaceuticals, previously ICN where he was Vice President Sales, Marketing and Business Development and built the European Pharmaceutical Business achieving sales growth from $30 million to $250 million. He also spent 20 years working for American Cyanamid, Lederle Laboratories holding various sales, marketing and General Management positions in Europe and the United States.
Mr. Vaughan-Griffiths will be based at the Company's European headquarters in Basel, Switzerland.
About Legacy Pharmaceuticals
Legacy Pharmaceuticals International GmbH is a customer-focused contract manufacturing and generic pharmaceutical company specializing in global manufacturing of prescription, over-the-counter (OTC), generic and cosmetic products at its plants in Humacao, Puerto Rico and Basel, Switzerland.
More information about Legacy can be found at www.LegacyPharm.com.
Source: Business Wire
Related Articles
- Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
- Sucampo Names Stanley G. Miele Head of Sales & Marketing
- MonoSol Rx Licenses Thin Film Formulation of Ondansetron to Strativa Pharmaceuticals, a Division of Par Pharmaceutical
- European Patient Safety and Parallel Pharmaceutical Trade - A Potential Public Health Disaster?
- Solvay Pharmaceuticals, Inc. And Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
- Cylene Pharmaceuticals Appoints David M. Ryckman, Ph.D. As Vice President of Manufacturing and Pharmaceutical Operations
- Jazz Pharmaceuticals, Inc. And Solvay Pharmaceuticals, Inc. Announce License Agreement for LUVOX(R) (Fluvoxamine Maleate) Tablets and Fluvoxamine Maleate Extended-Release Capsules in the United States
- Segments Analyzed Are Injectables, Solid Dosage Forms, and Liquid Dosage Forms for Pharmaceutical Contract Manufacturing 2000 - 2009
- TargetRx CEO Michael Luby to Drive Industry Dialogue on Bridging the Gap Between Sales & Marketing at Pharmaceutical Marketing Congress
- American Fiber Systems Names Former Choice One Communications Executive Michael D'Angelo as Vice President of Sales & Marketing
 |
 |
User Comments (0)
RSS Feeds